Viveve Medical (VIVE) 10-K 18 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 12, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		10,341,716
Entity Public Float			$ 8,858,275
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 6,523,000	$ 13,308,000
Accounts receivable, net of allowance for doubtful accounts of $124 and $407 as of December 31, 2020 and 2019, respectively	770,000	1,573,000
Inventory	3,254,000	4,861,000
Prepaid expenses and other current assets	2,296,000	2,447,000
Total current assets	12,843,000	22,189,000
Property and equipment, net	2,759,000	3,046,000
Investment in limited liability company	833,000	1,216,000
Other assets	195,000	526,000
Total assets	16,630,000	26,977,000
Current liabilities:
Accounts payable	881,000	1,608,000
Accrued liabilities	2,416,000	4,698,000
Paycheck Protection Program loan, current portion	918,000
Total current liabilities	4,215,000	6,306,000
Note payable, noncurrent portion	4,518,000	3,983,000
Paycheck Protection Program loan, noncurrent portion	425,000
Other noncurrent liabilities	498,000	167,000
Total liabilities	9,656,000	10,456,000
Commitments and contingences (Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 2,171,316 and 707,571 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively
Additional paid-in capital	226,800,000	214,432,000
Accumulated deficit	(219,826,000)	(197,911,000)
Total stockholders’ equity	6,974,000	16,521,000
Total liabilities and stockholders’ equity	16,630,000	26,977,000
Series A Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 124	$ 407
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	2,171,316	707,571
Common stock, shares outstanding (in shares)	2,171,316	707,571
Series A Preferred Stock [Member]
Convertible preferred stock, shares authorized (in shares)	547,345
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0	185,218
Convertible preferred stock, shares outstanding (in shares)	0	185,218
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	35,819	31,678
Convertible preferred stock, shares outstanding (in shares)	35,819	31,678

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 5,479,000	$ 6,567,000
Cost of revenue	5,183,000	5,551,000
Gross profit (loss)	296,000	1,016,000
Operating expenses:
Research and development	5,125,000	8,590,000
Selling, general and administrative	13,666,000	22,363,000
Restructuring costs		742,000
Total operating expenses	18,791,000	31,695,000
Loss from operations	(18,495,000)	(30,679,000)
Loss on debt restructuring		(6,705,000)
Modification of Series A and B warrants	(1,838,000)
Interest expense, net	(910,000)	(4,354,000)
Other expense, net	(289,000)	(161,000)
Net loss from consolidated companies	(21,532,000)	(41,899,000)
Loss from minority interest in limited liability company	(383,000)	(627,000)
Comprehensive and net loss	(21,915,000)	(42,526,000)
Series B convertible preferred stock dividends	(4,149,000)	(380,000)
Net loss attributable to common stockholders	$ (26,064,000)	$ (42,906,000)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (16.56)	$ (343.84)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	1,573,528	124,784

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	August 2019 ATM Facility [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	August 2019 ATM Facility [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	August 2019 ATM Facility [Member]Common Stock [Member]	August 2019 ATM Facility [Member]Additional Paid-in Capital [Member]	August 2019 ATM Facility [Member]Retained Earnings [Member]	August 2019 ATM Facility [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Purchase Agreement with LPC [Member]Common Stock [Member]	Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member]	Purchase Agreement with LPC [Member]Retained Earnings [Member]	Purchase Agreement with LPC [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Common Stock [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Retained Earnings [Member]	Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]	Series A and Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A and Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A and Series B Warrants [Member]Common Stock [Member]	Series A and Series B Warrants [Member]Additional Paid-in Capital [Member]	Series A and Series B Warrants [Member]Retained Earnings [Member]	Series A and Series B Warrants [Member]	Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Common Stock [Member]	Series A-2 and Series B-2 Warrants [Member]Additional Paid-in Capital [Member]	Series A-2 and Series B-2 Warrants [Member]Retained Earnings [Member]	Series A-2 and Series B-2 Warrants [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2018																																													46,363
Balances at Dec. 31, 2018																																														$ 160,297	$ (155,385)		$ 4,912
Stock offering, net of issuance costs (in shares)			100,418			100,423	547,342		194,595
Stock offering, net of issuance costs				$ 6,322		$ 6,322				$ 9,952		$ 9,952
Conversion of stock (in shares)																			(362,124)		362,124					31,300
Conversion of stock																												$ 35,413		$ 35,413
Series B convertible preferred stock dividends																																														(380)			(380)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																												378				378
Series B convertible preferred stock dividends paid in PIK shares																																														378			378
Stock-based compensation expense																																														2,251			2,251
Issuance of restricted common shares in connection with consulting agreement (in shares)																																													3,869
Issuance of restricted common shares in connection with consulting agreement																																														75			75
Issuance of common shares from employee stock purchase plan (in shares)																																													154
Issuance of common shares from employee stock purchase plan																																														56			56
Issuance of restricted stock awards to directors, employees and consultants (in shares)																																													118
Issuance of restricted stock awards to directors, employees and consultants																																														74			74
Reverse stock split - cancellation and payout of fractional shares (in shares)																																													(70)
Reverse stock split - cancellation and payout of fractional shares																																														(6)			(6)
Net loss																																															(42,526)		(42,526)
Balances (in shares) at Dec. 31, 2019																																											185,218	31,678	707,571
Balances at Dec. 31, 2019																																														214,432	(197,911)		16,521
Balances (in shares) at Dec. 31, 2018																																													46,363
Balances at Dec. 31, 2018																																														160,297	(155,385)		4,912
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																4,519
Balances (in shares) at Dec. 31, 2020																																												35,819	2,171,316
Balances at Dec. 31, 2020																																														226,800	(219,826)		6,974
Balances (in shares) at Dec. 31, 2019																																											185,218	31,678	707,571
Balances at Dec. 31, 2019																																														214,432	(197,911)		16,521
Stock offering, net of issuance costs (in shares)																																													52,500
Stock offering, net of issuance costs																																														341			341
Conversion of stock (in shares)																																											(185,218)		185,218
Conversion of stock
Series B convertible preferred stock dividends																																														(4,149)			(4,149)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																												4,141				4,141
Series B convertible preferred stock dividends paid in PIK shares																																														4,141			4,141
Stock-based compensation expense																																														2,577			2,577
Issuance of restricted common shares in connection with consulting agreement (in shares)																																													10,995
Issuance of restricted common shares in connection with consulting agreement																																														74			74
Issuance of common shares from employee stock purchase plan (in shares)																																													84
Issuance of common shares from employee stock purchase plan
Issuance of restricted stock awards to directors, employees and consultants (in shares)																																													25
Net loss																																															(21,915)		(21,915)
Issuance costs										$ (33)		$ (33)				$ (494)		$ (494)
Issuance of common shares in connection with warrant exercises (in shares)																																	1,115,863						93,129
Issuance of common shares in connection with warrant exercises																																		$ 7,814		$ 7,814				$ 593		$ 593
Modification of Series A and B warrants in connection with 2020 Warrant Offering																																		$ 1,838		$ 1,838
Issuance of Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																														1,838			1,838
Transaction costs in connection with warrant offering																																								$ (1,838)		$ (1,838)
Transaction costs in connection with warrant offering																																														(334)			(334)
Restricted stock awards
Reverse stock split - rounding adjustment (in shares)																																													5,931
Balances (in shares) at Dec. 31, 2020																																												35,819	2,171,316
Balances at Dec. 31, 2020																																														$ 226,800	$ (219,826)		$ 6,974

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (21,915,000)	$ (42,526,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	454,000	1,028,000
Depreciation and amortization	1,295,000	1,177,000
Stock-based compensation	2,651,000	2,400,000
Non-cash interest expense	535,000	1,577,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	2,000	5,000
Loss on debt restructuring		6,705,000
Loss from minority interest in limited liability company	383,000	627,000
Loss on disposal of property and equipment	20,000	108,000
Modification of Series A and B warrants	1,838,000
Changes in assets and liabilities:
Accounts receivable	349,000	3,103,000
Inventory	1,360,000	(1,070,000)
Prepaid expenses and other current assets	151,000	111,000
Other noncurrent assets	461,000	40,000
Accounts payable	(727,000)	(2,386,000)
Accrued and other liabilities	(2,422,000)	(1,536,000)
Other noncurrent liabilities	331,000	(599,000)
Net cash used in operating activities	(15,234,000)	(31,236,000)
Cash flows from investing activities:
Purchase of property and equipment	(781,000)	(1,087,000)
Net cash used in investing activities	(781,000)	(1,087,000)
Cash flows from financing activities:
Proceeds from exercise of common warrants	8,407,000
Transaction costs in connection with 2020 Warrant Offering	(334,000)
Proceeds from Paycheck Protection Program loan	1,343,000
Proceeds from intial purchase of common shares under Purchase Agreement with LPC	341,000
Proceeds from sale of common shares, net of issuance cost		16,274,000
Proceeds from issuance of common shares from employee stock purchase plan		56,000
Transaction costs in connection with note payable		(216,000)
Reverse stock split - cancellation and payout of fractional shares		(6,000)
Net cash provided by financing activities	9,230,000	16,108,000
Net decrease in cash and cash equivalents	(6,785,000)	(16,215,000)
Cash and cash equivalents - beginning of period	13,308,000	29,523,000
Cash and cash equivalents - end of period	6,523,000	13,308,000
Supplemental disclosure:
Cash paid for interest		2,508,000
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends	4,141,000	378,000
Issuance of note payable in settlement of accrued interest	532,000	1,226,000
Net transfer of equipment between inventory and property and equipment	247,000	207,000
Issuance of Series B convertible preferred stock and common stock warrants in connection with debt conversion		35,529,000
Operating cash outflows from operating leases	303,000	295,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)		629,000
November 2019 Offering [Member]
Cash flows from financing activities:
Transaction costs in connection with November 2019 Offering	(33,000)
Purchase Agreement with LPC [Member]
Cash flows from financing activities:
Transaction costs in connection with November 2019 Offering	$ (494,000)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2021 On January 19, 2021, “January 2021 $27,600,000, In connection with the closing of the public offering, on January 19, 2021, no one The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,223,000. A total of 2,450,880 January 2021 January 2021, no Elimination of Series A Convertible Preferred Stock On December 16, 2020, 547,345 $0.0001 November 25, 2019. no 547,345 Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 52,500 $6.50 may 25,000 50,000 12 no Other than as described above and Note 12 no 2020 On April 15, 2020, $15.50 $6.10 April 16, 2020, 482,059 24,279 $3,089,000. 2 482,059 2 24,279 $6.371 five April 20, 2020. 2020 $334,000. 12 December 31, 2020, 2 392,830 2 20,380 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $15.50 one a one $15.50 first a one $15.50 fifth 2 $15.50 one one a one $15.50 first a one $15.50 fifth The securities comprising the units were immediately separable and were issued separately. A total of 194,595 547,345 741,939 741,939 December 31, 2020, no December 31, 2020, no December 31, 2020, 325,632 11 12 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 989,379 7 5 120% $15.30 $18.36 one Liquidity and Management Plans Management evaluates whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity's ability to continue as a going concern and to meet its obligations as they become due within one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of December 31, 2020, $219,826,000, $6,523,000 $8,628,000. $15,234,000 December 31, 2020. $9,230,000 December 31, 2020, March 31, 2022. December 31, 2020. January 2021 $25,223,000 $9,700,000 To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Reverse Stock Split - September 2019 The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB's Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2020, one 36% December 31, 2019, one 16% There were no 10% December 31, 2020 2019. As of December 31, 2020, one 37% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $124,000 $407,000 December 31, 2020 2019, During the year ended December 31, 2020, $736,000 December 31, 2019, $905,000 Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2020 $2,818,000 $436,000 December 31, 2019 $4,051,000 $810,000 first first not As part of the Company's recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2020 2019. As part of the Company's normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2020 2019. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. December 31, 2020 2019, $1,337,000 $530,000. December 31, 2020 2019, $345,000 $662,000 December 31, 2020, $594,000 December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2020 2019. $17,000 $108,000, not December 31, 2020 December 31, 2019, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2020: December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $132,000 $486,000 December 31, 2020 2019, December 31, 2020 2019, $417,000 $143,000, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2020 2019, no Product Warranty The Company's products sold to customers are generally subject to warranties between one three not Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2020 2019. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2020 2019. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2020 2019, Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2020, no (b) As of December 31, 2020 2019, 35,819 31,678 2,341,111 2,70,458 1 65.36 $1,000 $15.30 not Other Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 2020 2019. The carrying amounts of the Company's financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2020 2019 There were no

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2020 2019 Life December 31, (in years) 2020 2019 Medical equipment 5 $ 3,111 $ 2,933 Rental program equipment 5 1,812 1,619 Computer equipment 3 242 243 Leasehold Improvements 3 122 122 Furniture and fixtures 7 386 385 Software 3 25 25 5,698 5,327 Less: Accumulated depreciation and amortization (2,939 ) (2,281 ) Property and equipment, net $ 2,759 $ 3,046 Depreciation and amortization expense for the years ended December 31, 2020 2019 $1,295,000 $1,177,000,

Note 5 - Investment in Limited

Note 5 - Investment in Limited Liability Company	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	5. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not December 31, 2020 2019, 485 300 $51,000 $26,000 $52,000 $27,000 December 31, 2020 2019, no December 31, 2020 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not December 31, 2020, 7% three December 31, 2020 2019, $383,000 $627,000, In February 2019, no

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2020 2019 December 31, December 31, 2020 2019 Accrued bonuses $ 744 $ 726 Accrued payroll and other related expenses 473 839 Deferred revenue - subscription rental program 345 662 Accrued professional fees 290 592 Current operating lease liabilities 132 268 Accrued inventory 87 474 Accrued sales commission 37 281 Customer contracts liabilities 17 108 Customer advances 14 53 Accrued interest 9 440 Other accruals 268 255 Total accrued liabilities $ 2,416 $ 4,698

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 In connection with the 2017 two 10 223 $9,500.00 12 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, December 31, 2019, $1,226,000, 5.0% As security for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 989,379 5 120% $15.30 $18.36 12 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company's ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. Pursuant to the amendment, the Company paid interest in-kind of $532,000 December 31, 2020, As of December 31, 2020, As of December 31, 2020 2019, $4,518,000 $3,983,000 March 31, 2023. The Company accounted for the changes in the 2017 31,300 989,379 November 26, 2019 $1,023.23 $32,027,000. 11 $3,502,000 12 $6,705,000, December 31, 2019. As of December 31, 2020, Year Ending December 31, 2021 $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,465 ) Present value of obligations 4,527 Less: Unamortized debt discount (9 ) Note payable, noncurrent portion $ 4,518

Note 8 - Paycheck Protection Pr

Note 8 - Paycheck Protection Program Loan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	8. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 24, 2020, $1,343,000 1.00% two ten may No In October 2020, 8 24 six 10 16 no two October 2020. no As of December 31, 2020, Year Ending December 31, 2021 $ 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 918 Paycheck Protection Program loan, noncurrent portion $ 425

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at December 31, 2020 2019. December 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 130 $ 395 Liabilities: Current operating lease liabilities $ 132 $ 268 Noncurrent operating lease liabilities - 132 $ 132 $ 400 The operating lease right-of-use assets are included in other assets on the consolidated balance sheets. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the consolidated balance sheets. The operating lease expense for the years ended December 31, 2020 2019 $300,000 $301,000, As of December 31, 2020, Year Ending December 31, 2021 $ 137 Total lease payments 137 Less: Amount representing interest (5 ) Present value of lease liabilities $ 132 The weighted average remaining lease term was approximately 5 December 31, 2020. December 31, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of December 31, 2020, Year Ending December 31, 2021 $ 345 Thereafter - Total $ 345 As of December 31, 2020, $841,000 December 31, 2020 2019 $462,000 $121,000,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 11 - Preferred Stock

Note 11 - Preferred Stock	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	11. Preferred Stock Series A Convertible Preferred Stock In connection with the closing of a public offering, on November 26, 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A convertible preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder's option into one A total of 547,345 November 2019 November December 2019, 362,127 December 31, 2019, 185,218 January February 2020, 185,218 On December 16, 2020, no 547,345 Series B Convertible Preferred Stock As previously reported (see Note 7 31,300 989,379 In connection with the CRG debt conversion, on November 26, 2019, 12.5% December 31, 2019, 378 $2,000 December 31, 2020, 4,141 $8,000 December 31, 2020, 35,819 no We have paid approximately $10,000 4,519 December 31, 2020. The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company's organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. Based on our valuation analysis, as of November 26, 2019, $1,023.23 $32,027,000 31,300 7 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not

Note 12 - Common Stock

Note 12 - Common Stock	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	12. Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 52,500 $6.50 may 25,000 may 30,000 not $10 may 50,000 not $20 may not $1,000,000. no In addition to Regular Purchases described above, the Company may not three 3 30% 95% Under certain circumstances and in accordance with the Purchase Agreement, the Company may Other than as described above, there are no Transaction costs in connection with the Purchase Agreement with LPC totaled approximately $494,000. $325,000. no 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $15.50 one one $15.50 first one $15.50 fifth 2 $15.50 one one one $15.50 first one $15.50 fifth The securities comprising the units were immediately separable and were issued separately. A total of 194,595 547,341 741,939 741,939 As of December 31, 2020, 11 As of December 31, 2020, no 325,632 ATM Equity Offerings Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. December 31, 2019, 100,423 August 2019 $6,322,000. December 31, 2019, no August 2019 In August 2019, November 2017 $25,000,000 December 31, 2019, zero November 2017 Restricted Common Shares The activity of restricted common shares for the year ended December 31, 2020 In March 2020, 2,832 $24,000. In June 2020, 3,453 $25,000. In September 2020, 4,709 $25,000. The activity of restricted common shares for the year ended December 31, 2019 In March 2019, 28 $25,000. In October 2019, 774 $25,000. In December 2019, 3,068 $25,000. Warrants for Common Stock As of December 31, 2020, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725 As of December 31, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 May 2015 Common Shares May 17, 2020 $ 4,240.00 22 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2020 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 2,473,785 In connection with the November 2019 741,939 741,939 one $15.50 first one $15.50 fifth one one $15.50 one five $15.50 $1,210,000 0%, 91.1%, 1.59% one $2,871,000 0%, 68.8%, 1.58% five $4,081,000 November 2019 In February 2020, 102,626 $1,591,000, 4,548 $70,000. On April 15, 2020, $15.50 $6.10 $6.10 $15.50 April 15, 2020, 718, 718 $1,838,000 Immediately Immediately before Modification After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 % On April 16, 2020, 482,059 24,279 $3,089,000. In conjunction, the Company also agreed to issue new Series A- 2 482,059 2 24,279 $6.371 five 2 2 $1,838,000 0%, 84.1%, of.35% five 2 2 April 20, 2020. 2020 $334,000. In May 2020, 410 $2,000. In June 2020, 2,761 $17,000, 5,070 $31,000. In August 2020, 111,704 $681,000, 380,913 $2,324,000. In August 2020, 89,230 2 $568,000, 3,899 2 $25,000. In September 2020, 1,500 $9,000. As of December 31, 2020, no 325,632 As of December 31, 2020, 2 392,830 2 20,380 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 989,379 15% November 2019 five 120% $15.30 $18.36 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 223 $9,500.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, December 31, 2020 2019, $3,000 $352,000, December 31, 2020, $9,000. During the year ended December 31, 2020, 1,209,000 $8,407,000. No December 31, 2019. No December 31, 2020 2019. A total of 42,404 December 31, 2020. 140 December 31, 2019.

Note 13 - Summary of Stock Opti

Note 13 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	13. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of December 31, 2020, 2006 12 no $9,920.00 2.1 The 2013 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, 2013 first January, 2013 4% In January 2019, 2019 2013 2,044 4,914 6,958 January 1, 2019. In September 2019, 2013 18% 1 $5.0 2 December 31, 2019. 2013 1,187,253 November 26, 2019. In January 2020, 2020 2013 263,993 1,187,253 1,451,246 January 1, 2020. As of December 31, 2020, 2013 986,387 466,200 $18.98 8.9 Activity under the 2006 2013 Year Ended December 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2019 4,098 $ 4,567.36 7.4 $ - Options granted 1,006,602 $ 11.42 Options exercised - Options canceled (1,867 ) $ 4,040.64 Options outstanding, December 31, 2019 1,008,833 $ 22.47 9.9 $ 3,928,715 Options granted 146,700 $ 6.36 Options exercised - Options canceled (169,134 ) $ 28.45 Options outstanding, December 31, 2020 986,399 $ 19.10 8.9 $ 675 Vested and exercisable and expected to vest, December 31, 2020 923,646 $ 19.77 8.9 $ 598 Vested and exercisable, December 31, 2020 245,445 $ 45.09 8.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company's closing share price as of December 31, 2020. The options outstanding and exercisable as of December 31, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2020 Price Term (Years) December 31, 2020 Price $4.45 - $8.91 967,288 $ 8.32 8.9 238,900 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 9.2 3,750 $ 13.60 $380.00 - $580.00 125 $ 552.00 8.4 113 $ 567.61 $1,000.00 - $1,970.00 1,954 $ 1,426.46 7.6 1,334 $ 1,437.21 $2,020.00 - $2,830.00 74 $ 2,501.22 7.0 53 $ 2,520.19 $3,110.00 - $3,580.00 189 $ 3,439.26 7.6 156 $ 3,455.90 $4,360.00 - $4,970.00 619 $ 4,549.77 6.2 510 $ 4,554.04 $5,010.00 - $5,670.00 300 $ 5,366.00 6.2 285 $ 5,356.84 $6,000.00 - $6,000.00 138 $ 6,000.00 5.0 138 $ 6,000.00 $7,140.00 - $7,920.00 200 $ 7,679.20 4.1 194 $ 7,676.29 $9,920.00 - $9,920.00 12 $ 9,920.00 2.1 12 $ 9,920.00 Total: 986,399 $ 19.10 8.9 245,445 $ 45.09 Deferred Restricted Stock Awards As of December 31, 2020, 234 During the year ended December 31, 2020, no 2013 In June 2020, 25 June 2018. In July 2019, 38 2013 $380.80 38 In June 2019, 25 June 2018. In April 2019, 53 2013 $910.00 53 In January 2019, 384 2013 2018 2018 50% 50% December 31, 2020, 18 December 31, 2019, 132 December 31, 2020, zero 2017 In August 2017, 2017 “2017 may 200 2017 85% first three September 2020, 2017 twelfth September 30, 2020. During the years ended December 31, 2020 2019, 2017 84 154 $1,000 $56,000, The Company estimated the fair value of purchase rights under the ESPP using the Black-Scholes option valuation model and the straight-line attribution approach. As of December 31, 2020, 2017 22 Stock-Based Compensation During the years ended December 31, 2020 2019, 146,700 1,006,602 $4.08 $7.23 no December 31, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2020 2019 Expected term (in years) 5 6 Average volatility 82 % 70 % Risk-free interest rate 0.37 % 1.62 % Dividend yield - - Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies' stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Cost of revenue $ 208 $ 135 Research and development 325 192 Selling, general and administrative 2,118 2,073 Total $ 2,651 $ 2,400 As of December 31, 2020, $4,781,000. 2.5

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes No no The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 The Company's effective tax rate is 0% December 31, 2020 2019. A reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows: Year Ended December 31, 2020 2019 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (4 )% Change in valuation allowance 20 % (39 )% Debt restructuring 0 % 6 % Limitation on net operating loss and credit carryovers 0 % 56 % Other 4 % 2 % Effective tax rate 0 % 0 % The components of the Company's net deferred tax assets and liabilities are as follows (in thousands): December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 20,891 $ 16,688 Capitalized start up costs 2,866 3,225 Research and development credits 631 527 Accruals and reserves 773 532 Fixed assets and depreciation 291 128 Total deferred tax assets 25,452 21,100 Deferred tax liabilities: Valuation allowance (25,452 ) (21,100 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on its past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $4,352,000 December 31, 2020 $16,506,000 December 31, 2019. As of December 31, 2020, $95,395,000 $20,239,000, not 2028. The Company also has California research and development tax credits of approximately $817,000. no Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three November 2019, no As of December 31, 2020, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2020 2019 Balance at the beginning of the year $ 223 $ 450 Additions (deletions) based upon tax positions related to the current year 22 (227 ) Balance at the end of the year $ 245 $ 223 If the ending balance of $245,000 December 31, 2020 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	15. Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2020, 855 38 $1,051,000 $4,889,000 December 31, 2020 2019, In August 2017, February 2019, no 5

Note 16 - Segments and Geograph

Note 16 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segments and Geographic Information The Company's long-lived assets by geographic area were as follows (in thousands): December 31, 2020 2019 United States $ 2,622 $ 2,818 Asia Pacific 76 64 Canada 54 142 Europe 7 22 Total $ 2,759 $ 3,046 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	17. Subsequent Events 2021 On January 19, 2021, “January 2021 $27,600,000, The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,223,000. Series C Convertible Preferred Stock In connection with the closing of a public offering, on January 19, 2021, With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder's option into one A total of 2,450,880 January 2021 January 2021, no 2013 2021 Effective January 1, 2021, 2013 307,705 1,451,246 1,758,951 2013 November 2019 Amendment to Warrant Pricing Terms On January 19, 2021, $3.40 2 2 one $3.40. $6.10 $3.40 2 2 $6.371 $3.40 no Annual Equity Awards In January 2021, 690,000 2013 second Office Lease Amendment In March 2021, 34 March 31, 2024. second third $21,028, $21,643 $22,258 June 2021. $19,000.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Reverse Stock Split - September 2019 The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB's Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2020, one 36% December 31, 2019, one 16% There were no 10% December 31, 2020 2019. As of December 31, 2020, one 37% December 31, 2019, two 49%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $124,000 $407,000 December 31, 2020 2019, During the year ended December 31, 2020, $736,000 December 31, 2019, $905,000
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2020 $2,818,000 $436,000 December 31, 2019 $4,051,000 $810,000 first first not As part of the Company's recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2020 2019. As part of the Company's normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2020 2019.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. December 31, 2020 2019, $1,337,000 $530,000. December 31, 2020 2019, $345,000 $662,000 December 31, 2020, $594,000 December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2020 2019. $17,000 $108,000, not December 31, 2020 December 31, 2019, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2020: December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $132,000 $486,000 December 31, 2020 2019, December 31, 2020 2019, $417,000 $143,000, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2020 2019, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company's products sold to customers are generally subject to warranties between one three not
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2020 2019.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2020 2019. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2020 2019,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2020, no (b) As of December 31, 2020 2019, 35,819 31,678 2,341,111 2,70,458 1 65.36 $1,000 $15.30 not
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2020 2019 Medical equipment 5 $ 3,111 $ 2,933 Rental program equipment 5 1,812 1,619 Computer equipment 3 242 243 Leasehold Improvements 3 122 122 Furniture and fixtures 7 386 385 Software 3 25 25 5,698 5,327 Less: Accumulated depreciation and amortization (2,939 ) (2,281 ) Property and equipment, net $ 2,759 $ 3,046

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2020 2019 Accrued bonuses $ 744 $ 726 Accrued payroll and other related expenses 473 839 Deferred revenue - subscription rental program 345 662 Accrued professional fees 290 592 Current operating lease liabilities 132 268 Accrued inventory 87 474 Accrued sales commission 37 281 Customer contracts liabilities 17 108 Customer advances 14 53 Accrued interest 9 440 Other accruals 268 255 Total accrued liabilities $ 2,416 $ 4,698

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2020
The 2017 Loan Agreement [Member]
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2021 $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,465 ) Present value of obligations 4,527 Less: Unamortized debt discount (9 ) Note payable, noncurrent portion $ 4,518

Note 8 - Paycheck Protection _2

Note 8 - Paycheck Protection Program Loan (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Year Ending December 31, 2021 $ 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 918 Paycheck Protection Program loan, noncurrent portion $ 425

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	December 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 130 $ 395 Liabilities: Current operating lease liabilities $ 132 $ 268 Noncurrent operating lease liabilities - 132 $ 132 $ 400
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2021 $ 137 Total lease payments 137 Less: Amount representing interest (5 ) Present value of lease liabilities $ 132
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2021 $ 345 Thereafter - Total $ 345

Note 12 - Common Stock (Tables)

Note 12 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725 Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 May 2015 Common Shares May 17, 2020 $ 4,240.00 22 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2020 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 2,473,785
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Immediately Immediately before Modification After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 %

Note 13 - Summary of Stock Op_2

Note 13 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Year Ended December 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2019 4,098 $ 4,567.36 7.4 $ - Options granted 1,006,602 $ 11.42 Options exercised - Options canceled (1,867 ) $ 4,040.64 Options outstanding, December 31, 2019 1,008,833 $ 22.47 9.9 $ 3,928,715 Options granted 146,700 $ 6.36 Options exercised - Options canceled (169,134 ) $ 28.45 Options outstanding, December 31, 2020 986,399 $ 19.10 8.9 $ 675 Vested and exercisable and expected to vest, December 31, 2020 923,646 $ 19.77 8.9 $ 598 Vested and exercisable, December 31, 2020 245,445 $ 45.09 8.6 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2020 Price Term (Years) December 31, 2020 Price $4.45 - $8.91 967,288 $ 8.32 8.9 238,900 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 9.2 3,750 $ 13.60 $380.00 - $580.00 125 $ 552.00 8.4 113 $ 567.61 $1,000.00 - $1,970.00 1,954 $ 1,426.46 7.6 1,334 $ 1,437.21 $2,020.00 - $2,830.00 74 $ 2,501.22 7.0 53 $ 2,520.19 $3,110.00 - $3,580.00 189 $ 3,439.26 7.6 156 $ 3,455.90 $4,360.00 - $4,970.00 619 $ 4,549.77 6.2 510 $ 4,554.04 $5,010.00 - $5,670.00 300 $ 5,366.00 6.2 285 $ 5,356.84 $6,000.00 - $6,000.00 138 $ 6,000.00 5.0 138 $ 6,000.00 $7,140.00 - $7,920.00 200 $ 7,679.20 4.1 194 $ 7,676.29 $9,920.00 - $9,920.00 12 $ 9,920.00 2.1 12 $ 9,920.00 Total: 986,399 $ 19.10 8.9 245,445 $ 45.09
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2020 2019 Expected term (in years) 5 6 Average volatility 82 % 70 % Risk-free interest rate 0.37 % 1.62 % Dividend yield - -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2020 2019 Cost of revenue $ 208 $ 135 Research and development 325 192 Selling, general and administrative 2,118 2,073 Total $ 2,651 $ 2,400

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (4 )% Change in valuation allowance 20 % (39 )% Debt restructuring 0 % 6 % Limitation on net operating loss and credit carryovers 0 % 56 % Other 4 % 2 % Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 20,891 $ 16,688 Capitalized start up costs 2,866 3,225 Research and development credits 631 527 Accruals and reserves 773 532 Fixed assets and depreciation 291 128 Total deferred tax assets 25,452 21,100 Deferred tax liabilities: Valuation allowance (25,452 ) (21,100 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2020 2019 Balance at the beginning of the year $ 223 $ 450 Additions (deletions) based upon tax positions related to the current year 22 (227 ) Balance at the end of the year $ 245 $ 223

Note 16 - Segments and Geogra_2

Note 16 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	December 31, 2020 2019 United States $ 2,622 $ 2,818 Asia Pacific 76 64 Canada 54 142 Europe 7 22 Total $ 2,759 $ 3,046

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Jan. 19, 2021	Jun. 09, 2020	Jun. 08, 2020	Apr. 20, 2020	Apr. 16, 2020	Nov. 12, 2019	Sep. 30, 2020	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Nov. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 31, 2021	Jan. 18, 2021	Dec. 16, 2020	Apr. 15, 2020
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																2,473,785
Preferred Stock, Shares Authorized (in shares)															10,000,000	10,000,000
Proceeds from Warrant Exercises															$ 8,407,000
Payments of Warrant Issuance Costs				$ 334,000											334,000
Debt Conversion, Converted Instrument, Amount																35,529,000
Retained Earnings (Accumulated Deficit), Ending Balance															(219,826,000)	(197,911,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance															6,523,000	13,308,000
Working Capital															8,628,000
Net Cash Provided by (Used in) Operating Activities, Total															(15,234,000)	(31,236,000)
Net Cash Provided by (Used in) Financing Activities, Total															$ 9,230,000	$ 16,108,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)						$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)						$ 18.36
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount						$ 28,981,000
Debt Conversion, Converted Instrument, Amount						$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						31,300
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																$ 15.50				$ 6.10
Proceeds from Warrant Exercises					$ 3,089,000
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50			$ 18.36
Warrants and Rights Outstanding, Term (Year)												1 year	1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												741,939	741,939			989,379
Stock Issued During Period, Shares, Warrant Exercises (in shares)					482,059			111,704	2,761	410	102,626
Proceeds from Warrant Exercises								$ 681,000	$ 17,000	$ 2,000	$ 1,591,000
Class of Warrant or Right, Outstanding (in shares)															0
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50			$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												741,939	741,939		325,632	741,940
Stock Issued During Period, Shares, Warrant Exercises (in shares)					24,279		1,500	380,913	5,070		4,548
Proceeds from Warrant Exercises							$ 9,000	$ 2,324,000	$ 31,000		$ 70,000
Class of Warrant or Right, Outstanding (in shares)															325,632
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				482,059											392,830
Stock Issued During Period, Shares, Warrant Exercises (in shares)								89,230							392,830
Proceeds from Warrant Exercises								$ 568,000
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				24,279											20,380
Stock Issued During Period, Shares, Warrant Exercises (in shares)								3,899							20,380
Proceeds from Warrant Exercises								$ 25,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 6.371
Warrants and Rights Outstanding, Term (Year)				5 years
Class of Warrant or Right, Outstanding (in shares)				1,838,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																$ 15.50
Warrants and Rights Outstanding, Term (Year)						5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						989,379										741,940
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate						120.00%
Class A Units [Member] | Series A Warrants [Member]
Warrants Per Unit (in shares)												1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50
Warrants and Rights Outstanding, Term (Year)												1 year	1 year
Class A Units [Member] | Series B Warrants [Member]
Warrants Per Unit (in shares)												1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years	5 years
Class B Units [Member] | Series A Warrants [Member]
Warrants Per Unit (in shares)												1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50
Warrants and Rights Outstanding, Term (Year)												1 year	1 year
Class B Units [Member] | Series B Warrants [Member]
Warrants Per Unit (in shares)												1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 15.50	$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years	5 years
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)															52,500
Common Stock [Member] | Series A and Series B Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)															1,115,863
Common Stock [Member] | Series A-2 and Series B-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)															93,129
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)												1	1		1	1
Stock Issued During Period, Shares, New Issues (in shares)												547,345
Preferred Stock, Shares Outstanding, Ending Balance (in shares)															0	185,218			0
Preferred Stock, Shares Authorized (in shares)															547,345				547,345
Preferred Stock, Par or Stated Value Per Share (in dollars per share)															$ 0.0001	$ 0.0001			$ 0.0001
Subsequent Event [Member] | Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40																	$ 6.10
Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40																	$ 6.371
Subsequent Event [Member] | Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Warrants and Rights Outstanding, Term (Year)	5 years
Subsequent Event [Member] | Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Warrants and Rights Outstanding, Term (Year)	5 years
Subsequent Event [Member] | Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																	0
January 2021 Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 27,600,000
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs	$ 25,223,000
January 2021 Offering [Member] | Subsequent Event [Member] | Class A Units [Member]
Units Issued, Shares (in shares)	4,607,940
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Common Shares Per Unit (in shares)	1
January 2021 Offering [Member] | Subsequent Event [Member] | Class B Units [Member]
Units Issued, Shares (in shares)	2,450,880
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Series C Convertible Preferred Stock Per Unit (in shares)	1
January 2021 Offering [Member] | Subsequent Event [Member] | Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	1
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880
Over-Allotment Option [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,058,820
Over-Allotment Option [Member] | Subsequent Event [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,058,820
Purchase Agreement with LPC [Member]
Shares Issued, Price Per Share (in dollars per share)		$ 6.50
Stock Issued During Period, Shares, New Issues (in shares)		52,500
Maximum Amount of Shares Issuable			$ 10,000,000
Stock Purchase Agreement Duration Period (Month)			2 years 180 days
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares)		25,000
Maximum Number of Shares Issuable on Any Business Day Selected by The Company in Certain Circumstances (in shares)		50,000
Purchase Agreement with LPC [Member] | Forecast [Member]
Proceeds from Issuance or Sale of Equity, Total														$ 9,700,000
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total												$ 11,500,000
Shares Issued, Price Per Share (in dollars per share)												$ 15.50	$ 15.50
Common Shares Per Unit (in shares)												1	1
Proceeds From Issuance of Common Stock, Net												$ 9,922,000
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share)												$ 15.50	$ 15.50
Common Shares Per Unit (in shares)												1	1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share)												$ 15.50	$ 15.50
Series A Convertible Preferred Stock Per Unit (in shares)												1	1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												194,595	194,595			194,595
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												547,345	547,341
November 2019 Offering [Member] | Series A Preferred Stock [Member] | Class B Units [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)												1	1

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Dec. 01, 2020USD ($)shares	Sep. 18, 2019USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 16, 2020shares	Nov. 30, 2019shares	Jan. 01, 2019USD ($)
Common Stock, Shares Authorized (in shares) | shares			75,000,000	75,000,000
Reverse Stock Split, Rounding Adjustment (in shares) | shares	5,931
Payments for Fractional Shares of Reverse Stock Split	$ 0	$ 6,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001	$ 0.0001
Operating Lease, Right-of-Use Asset			$ 130,000	$ 395,000			$ 629,000
Number of Financial Institutions			1
Accounts Receivable, Allowance for Credit Loss, Ending Balance			$ 124,000	407,000
Accounts Receivable, Allowance for Credit Loss, Writeoff			736,000	905,000
Inventory, Finished Goods, Net of Reserves			2,818,000	4,051,000
Inventory, Raw Materials, Net of Reserves			436,000	810,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total			5,479,000	6,567,000
Deferred Income			345,000	662,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total			0	0
Contract with Customer, Liability, Total			17,000	108,000
Capitalized Contract Cost, Net, Total			132,000	486,000
Capitalized Contract Cost, Amortization			417,000	143,000
Capitalized Contract Cost, Impairment Loss			0
Equity Method Investment, Other than Temporary Impairment			$ 0	$ 0
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares			1	1		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares			0	185,218	0
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares			2,341,111	270,458
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares			35,819	31,678
Conversion of Stock Exchange Ratio			65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares			$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares			$ 15.30
Rental [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 1,337,000	$ 530,000
Rental Program Equipment [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total			594,000
Marketing Programs [Member]
Contract with Customer, Liability, Total			$ 17,000	$ 108,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Warranty Period (Year)			1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			7 years
Warranty Period (Year)			3 years
Viveve Systems [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers			1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage			36.00%	16.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers			1	2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage			37.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage				49.00%
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total			$ 132,000	$ 400,000			$ 629,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10	100

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Other assets		$ 195	$ 526	$ 800	$ 171
Total assets		16,630	26,977	47,463	46,834
Total accrued liabilities		2,416	4,698	6,996	6,766
Total current liabilities		4,215	6,306	10,990	10,760
Other noncurrent liabilities		498	167	1,033	634
Total liabilities		9,656	10,456	42,551	41,922
Total liabilities and stockholders' equity		$ 16,630	$ 26,977	47,463	$ 46,834
Accounting Standards Update 2016-02 [Member]
Other assets	[1]			629
Total assets	[1]			629
Total accrued liabilities	[2]			230
Total current liabilities	[2]			230
Other noncurrent liabilities	[2]			399
Total liabilities	[2]			629
Total liabilities and stockholders' equity	[2]			$ 629
[1]	Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent.
[2]	Represents recognition of operating lease liabilities.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Customer contract liabilities	$ 17,000	$ 108,000
Change in customer contract liabilities	(91,000)
Marketing Programs [Member]
Customer contract liabilities	17,000	$ 108,000
Change in customer contract liabilities	$ (91,000)

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 5,479	$ 6,567
Asia Pacific [Member]
Revenue	2,732	2,349
North America [Member]
Revenue	2,537	3,672
CANADA
Revenue	110	277
Europe And Middle East [Member]
Revenue	86	254
Latin America [Member]
Revenue	$ 14	$ 15

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2020		Dec. 31, 2019
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		[1]	185,218
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,341,111	[2]	2,070,458
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	1,728,725		2,473,785
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	986,399		1,008,833
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	394		277
[1]	Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock. As of December 31, 2020, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding.
[2]	As of December 31, 2020 and 2019, a total of 35,819 and 31,678 shares of Series B convertible preferred stock were outstanding and convertible into 2,341,111 and 2,70,458 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 1,295,000	$ 1,177,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 5,698	$ 5,327
Less: Accumulated depreciation and amortization	(2,939)	(2,281)
Property and equipment, net	$ 2,759	3,046
Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 3,111	2,933
Rental Program Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 1,812	1,619
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 242	243
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 122	122
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Property and equipment, gross	$ 386	385
Software [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 25	$ 25

Note 5 - Investment in Limite_2

Note 5 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Income (Loss) from Equity Method Investments, Total		$ (383,000)	$ (627,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%
Income (Loss) from Equity Method Investments, Total		$ 383,000	$ 627,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		485	300
Unrecorded Unconditional Purchase Obligation, Purchases		$ 51,000	$ 26,000
Payments for Purchase of Products		52,000	27,000
Accounts Payable, Related Parties, Current		$ 0	$ 0
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Accrued bonuses	$ 744	$ 726
Accrued payroll and other related expenses	473	839
Deferred revenue - subscription rental program	345	662
Accrued professional fees	290	592
Accrued inventory	87	474
Accrued sales commission	37	281
Accrued interest	9	440
Other accruals	268	255
Total accrued liabilities	2,416	4,698	$ 6,996	$ 6,766
Customer Contracts Liabilites [Member]
Contract with customer, liability	17	108
Customer Advances [Member]
Contract with customer, liability	14	53
Accrued Liabilities [Member]
Current operating lease liabilities	$ 132	$ 268

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	Nov. 12, 2019	Dec. 29, 2017	May 22, 2017	Dec. 31, 2020	Dec. 31, 2019	Nov. 26, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,473,785
Debt Conversion, Converted Instrument, Amount					$ 35,529,000
Notes Payable, Noncurrent, Total				4,518,000	3,983,000
Warrants and Rights Outstanding					3,502,000
Gains (Losses) on Restructuring of Debt					$ (6,705,000)
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share)				$ 15.30
Preferred Stock, Fair Value, Per Share (in dollars per share)						$ 1,023.23
Convertible Preferred Stock, Fair Value						$ 32,027,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 18.36
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount	$ 28,981,000
Debt Conversion, Converted Instrument, Amount	$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)			10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			223		223
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 9,500		$ 9,500
Warrants and Rights Outstanding			$ 940,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	989,379				741,940
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 15.50
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate	120.00%
Warrants and Rights Outstanding	$ 3,502,000
The 2017 Loan Agreement [Member]
Notes Payable, Noncurrent, Total				$ 4,518,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount			20,000,000
Debt Agreement, Covenant, Additional Funding			10,000,000
Debt Agreement, Maximum Borrowing Capacity			$ 30,000,000
Proceeds from Lines of Credit, Total		$ 10,000,000
Debt Instrument, Term (Year)			6 years
Debt instrument, Interest Only Payment, Period (Year)			4 years
Debt Instrument, Interest Rate, Stated Percentage			12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period			4.00%
Paid-in-Kind Interest				532,000	$ 1,226,000
Debt Instrument, Prepayment Fee, Percentage			5.00%
Debt Instrument, Back-end Facility Fee Percentage of Principal	25.00%		5.00%
Notes Payable, Noncurrent, Total				$ 4,518,000	$ 3,983,000

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Less: Unamortized debt discount	$ (9,000)
Note payable, noncurrent portion	4,518,000	$ 3,983,000
The 2017 Loan Agreement [Member]
2021
2022
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(1,465,000)
Present value of obligations	4,527,000
Less: Unamortized debt discount	(9,000)
Note payable, noncurrent portion	$ 4,518,000

Note 8 - Paycheck Protection _3

Note 8 - Paycheck Protection Program Loan (Details Textual) - USD ($)	Apr. 24, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of Unsecured Debt		$ 1,343,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Unsecured Debt	$ 1,343,000

Note 8 - Paycheck Protection _4

Note 8 - Paycheck Protection Program Loan - Summary of Paycheck Protection Program Loan (Details) - Paycheck Protection Program CARES Act [Member] $ in Thousands	Dec. 31, 2020USD ($)
2021	$ 938
2022	426
Total payments	1,364
Less: Amount representing interest	(20)
Present value of obligations	1,344
Paycheck Protection Program loan,current portion	918
Paycheck Protection Program loan, noncurrent portion	$ 425

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Feb. 01, 2017USD ($)ft²
Operating Lease, Expense		$ 300,000	$ 301,000
Operating Lease, Weighted Average Remaining Lease Term (Month)		150 days
Operating Lease, Weighted Average Discount Rate, Percent		12.50%
Operating Lease, Property Plant and Equipment, Amount		$ 841,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²				12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year				20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year				21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year				21.75
Security Deposit				$ 22,000
Operating Leases, Allowance for Certain Improvements				$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)	3 years
Operating Leases, Monthly Payment	$ 3,000
Leases of Viveve Systems [Member]
Lessor, Operating Lease, Depreciation on Leased Assets		$ 462,000	$ 121,000

Note 9 - Leases - Lease Assets

Note 9 - Leases - Lease Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 130,000	$ 395,000	$ 629,000
Accrued Liabilities [Member]
Current operating lease liabilities	132,000	268,000
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities		132,000
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 132,000	$ 400,000	$ 629,000

Note 9 - Leases - Maturity of O

Note 9 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
2021	$ 137,000
Total lease payments	137,000
Less: Amount representing interest	(5,000)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 132,000	$ 400,000	$ 629,000

Note 9 - Leases - Minimum Futur

Note 9 - Leases - Minimum Future Rentals (Details) $ in Thousands	Dec. 31, 2020USD ($)
2021	$ 345
Thereafter
Total	$ 345

Note 11 - Preferred Stock (Deta

Note 11 - Preferred Stock (Details Textual) - USD ($)	Nov. 26, 2019	Nov. 12, 2019	Nov. 30, 2019	Feb. 29, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 16, 2020
Preferred Stock, Shares Authorized (in shares)					10,000,000	10,000,000	10,000,000	10,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,473,785		2,473,785
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		989,379			741,940		741,940
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		31,300
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				185,218	362,127
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			1		1	1	1	1
Stock Issued During Period, Shares, New Issues (in shares)			547,345
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					185,218	0	185,218	0	0
Preferred Stock, Shares Authorized (in shares)						547,345		547,345	547,345
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					270,458	2,341,111	270,458	2,341,111
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					31,678	35,819	31,678	35,819
Preferred Stock, Dividend Rate, Percentage	12.50%
Preferred Stock Dividends, Shares (in shares)						4,141	378	4,519
Dividends, Preferred Stock, Cash						$ 8,000	$ 2,000	$ 10,000
Preferred Stock, Fair Value, Per Share (in dollars per share)	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)	31,300

Note 12 - Common Stock (Details

Note 12 - Common Stock (Details Textual)	Jun. 09, 2020USD ($)$ / sharesshares	Jun. 08, 2020USD ($)	Apr. 20, 2020USD ($)$ / sharesshares	Apr. 16, 2020USD ($)shares	Sep. 30, 2020USD ($)shares	Aug. 31, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	May 31, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Feb. 29, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Nov. 30, 2019USD ($)$ / sharesshares	Oct. 31, 2019USD ($)shares	Aug. 31, 2019USD ($)	Mar. 31, 2019USD ($)shares	Nov. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 16, 2020shares	Apr. 15, 2020$ / shares	Nov. 12, 2019USD ($)$ / sharesshares	May 22, 2017USD ($)$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											2,473,785							2,473,785
Stock Issued During Period, Share, Restricted Common Shares (in shares)					4,709		3,453		2,832		3,068		774		28
Stock Issued During Period, Value, Restricted Common Shares | $					$ 25,000		$ 25,000		$ 24,000		$ 25,000		$ 25,000		$ 25,000		$ 74,000	$ 75,000
Warrants and Rights Outstanding | $											$ 3,502,000							3,502,000
Proceeds from Warrant Exercises | $																	8,407,000
Fair Value Adjustment of Warrants | $																	1,838,000
Payments of Warrant Issuance Costs | $			$ 334,000														334,000
Amortization of Debt Discount (Premium) | $																	3,000	$ 352,000
Debt Instrument, Unamortized Discount, Total | $																	$ 9,000
Class of Warrants or Rights, Exercises in Period (in shares)																	1,209,000	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)																	0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares)																	42,404	140
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total | $																	$ 790,000
Debt Instrument, Unamortized Discount, Total | $																	$ 9,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																					$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																					$ 18.36
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												547,345
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)											1	1				1	1	1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											185,218						0	185,218	0
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 18.36	$ 15.50				$ 15.50		$ 18.36
Warrants and Rights Outstanding, Term (Year)												1 year				1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											989,379	741,939				741,939		989,379
Warrants and Rights Outstanding | $												$ 1,210,000				$ 1,210,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)				482,059		111,704	2,761	410		102,626
Proceeds from Warrant Exercises | $						$ 681,000	$ 17,000	$ 2,000		$ 1,591,000
Class of Warrant or Right, Outstanding (in shares)																	0
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input												0				0
Series A Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input												91.1				91.1
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input												1.59				1.59
Series A Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input												1				1
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 15.50	$ 15.50				$ 15.50		$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											741,940	741,939				741,939	325,632	741,940
Warrants and Rights Outstanding | $												$ 2,871,000				$ 2,871,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)				24,279	1,500	380,913	5,070			4,548
Proceeds from Warrant Exercises | $					$ 9,000	$ 2,324,000	$ 31,000			$ 70,000
Class of Warrant or Right, Outstanding (in shares)																	325,632
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input												0				0
Series B Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input												0.688				0.688
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input												0.0158				0.0158
Series B Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input												5				5
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 15.50							$ 15.50		$ 6.10
Warrants and Rights Outstanding | $												$ 4,081,000				$ 4,081,000
Proceeds from Warrant Exercises | $				$ 3,089,000
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			482,059														392,830
Stock Issued During Period, Shares, Warrant Exercises (in shares)						89,230											392,830
Proceeds from Warrant Exercises | $						$ 568,000
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			24,279														20,380
Stock Issued During Period, Shares, Warrant Exercises (in shares)						3,899											20,380
Proceeds from Warrant Exercises | $						$ 25,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 6.371
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Outstanding (in shares)			1,838,000
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			0.00841
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.35
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input			5
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 15.50							$ 15.50
Warrants and Rights Outstanding, Term (Year)																					5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											741,940							741,940			989,379
Warrants and Rights Outstanding | $																					$ 3,502,000
Class of Warrants or Rights, Outstanding, Percentage of Common Stock																					15.00%
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate																					120.00%
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																					0
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																					0.688
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																					0.0158
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																					5
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 9,500							$ 9,500				$ 9,500
Warrants and Rights Outstanding, Term (Year)																						10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											223							223				223
Warrants and Rights Outstanding | $																						$ 940,000
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																						0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																						55.1
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																						2.25
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																						10
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Warrants and Rights Outstanding, Term (Year)												1 year				1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years				5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Warrants and Rights Outstanding, Term (Year)												1 year				1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Warrants and Rights Outstanding, Term (Year)												5 years				5 years
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																	52,500
Stock Issued During Period, Share, Restricted Common Shares (in shares)																	10,995	3,869
Stock Issued During Period, Value, Restricted Common Shares | $
Common Stock [Member] | Series A and Series B Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)																	1,115,863
Common Stock [Member] | Series A-2 and Series B-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)																	93,129
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable | $		$ 10,000,000
Stock Purchase Agreement Duration Period (Month)		2 years 180 days
Stock Issued During Period, Shares, New Issues (in shares)	52,500
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 6.50
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares)	25,000
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $10.00 (in shares)	30,000
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $20.00 (in shares)	50,000
Maximum Number of Shares Issuable Any single Regular Purchase (in shares)	1,000,000
Payments of Stock Issuance Costs | $	$ 494,000																$ 494,000
Purchase Agreement with LPC [Member] | Commitment Fee [Member]
Payments of Stock Issuance Costs | $	$ 325,000
November 2019 Offering [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Payments of Stock Issuance Costs | $																	$ 33,000
Proceeds from Issuance or Sale of Equity, Total | $												$ 11,500,000
Proceeds From Issuance of Common Stock, Net | $												$ 9,922,000
Common Shares Per Unit (in shares)												1				1
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												547,345				547,341
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Common Shares Per Unit (in shares)												1				1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares												$ 15.50				$ 15.50
Series A Convertible Preferred Stock Per Unit (in shares)												1				1
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)												1				1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												194,595				194,595		194,595
August 2019 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		100,423
Proceeds From Issuance of Common Stock, Net | $																		$ 6,322,000
Aggregate Offering Price | $														$ 6,760,000
Common Stock, Shares, Remaining Shares to be Issued (in shares)											0							0
August 2019 ATM Facility [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		100,418
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		0
Aggregate Offering Price | $														$ 25,000,000

Note 12 - Common Stock - Summar

Note 12 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2019	Nov. 12, 2019	May 22, 2017
Shares Outstanding Under Warrants (in shares)		2,473,785
Warrant One [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4,000
Shares Outstanding Under Warrants (in shares)	79
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date		Feb. 17, 2025
Exercise Price (in dollars per share)		$ 4,000
Shares Outstanding Under Warrants (in shares)		79
Warrant Two [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2,720
Shares Outstanding Under Warrants (in shares)	2
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date		Mar. 26, 2025
Exercise Price (in dollars per share)		$ 2,720
Shares Outstanding Under Warrants (in shares)		2
Warrant Three [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4,240
Shares Outstanding Under Warrants (in shares)	37
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date		May 12, 2025
Exercise Price (in dollars per share)		$ 4,240
Shares Outstanding Under Warrants (in shares)		37
Warrant Four [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5,600
Shares Outstanding Under Warrants (in shares)	31
May 2015 Issuance Second Contractor [Member]
Expiration Date		May 17, 2020
Exercise Price (in dollars per share)		$ 4,240
Shares Outstanding Under Warrants (in shares)		22
Warrant Five [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6,080
Shares Outstanding Under Warrants (in shares)	25
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date		Dec. 16, 2025
Exercise Price (in dollars per share)		$ 5,600
Shares Outstanding Under Warrants (in shares)		31
Warrant Six [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7,740
Shares Outstanding Under Warrants (in shares)	6
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date		Apr. 1, 2026
Exercise Price (in dollars per share)		$ 6,080
Shares Outstanding Under Warrants (in shares)		25
Warrant Seven [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4,980
Shares Outstanding Under Warrants (in shares)	101
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date		May 11, 2021
Exercise Price (in dollars per share)		$ 7,740
Shares Outstanding Under Warrants (in shares)		6
Warrant Eight [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9,500
Shares Outstanding Under Warrants (in shares)	223
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date		Jun. 20, 2026
Exercise Price (in dollars per share)		$ 4,980
Shares Outstanding Under Warrants (in shares)		101
Warrant Nine [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 6.10
Shares Outstanding Under Warrants (in shares)	325,632
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date		May 25, 2027
Exercise Price (in dollars per share)		$ 9,500			$ 9,500
Shares Outstanding Under Warrants (in shares)		223			223
Warrant Ten [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 18.36
Shares Outstanding Under Warrants (in shares)	989,379
Series A Warrants [Member]
Expiration Date		Nov. 26, 2020
Exercise Price (in dollars per share)		$ 18.36	$ 15.50
Shares Outstanding Under Warrants (in shares)		989,379	741,939
Warrant Eleven [Member]
Expiration Date	Apr. 21, 2025
Exercise Price (in dollars per share)	$ 6.37
Shares Outstanding Under Warrants (in shares)	413,210
Series B Warrants [Member]
Expiration Date		Nov. 26, 2024
Exercise Price (in dollars per share)		$ 15.50	$ 15.50
Shares Outstanding Under Warrants (in shares)	325,632	741,940	741,939
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Expiration Date		Nov. 26, 2024
Exercise Price (in dollars per share)		$ 15.50
Shares Outstanding Under Warrants (in shares)		741,940		989,379
Warrant Twelve [Member]
Shares Outstanding Under Warrants (in shares)	1,728,725

Note 12 - Common Stock - Assump

Note 12 - Common Stock - Assumptions (Details) - Warrant [Member]	Apr. 15, 2020	Apr. 14, 2020
Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	6.1	15.5
Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	6.3	6.3
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	2.8	2.8
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.97	0.97
Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0027	0.0027
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0

Note 13 - Summary of Stock Op_3

Note 13 - Summary of Stock Options (Details Textual) - USD ($)	Aug. 22, 2016	Jun. 30, 2020	Jan. 31, 2020	Sep. 30, 2019	Jul. 31, 2019	Jun. 30, 2019	Apr. 30, 2019	Jan. 31, 2019	Aug. 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2020	Nov. 26, 2019	Jan. 01, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)										986,399	1,008,833	4,098
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)										$ 19.10	$ 22.47	$ 4,567.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)										8 years 328 days	9 years 328 days	7 years 146 days
Proceeds from Stock Plans											$ 56,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)										146,700	1,006,602
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)		25				25
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					38		53
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)					38		53
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 380.80		$ 910
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate										0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total										$ 4,781,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										2 years 182 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)										12
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)										0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)										$ 9,920
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)										2 years 36 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)										986,387
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)										466,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)										$ 18.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)										8 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum										10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)			263,993					2,044
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)										1,451,246		4,914	1,451,246	1,187,253	6,958
Common Stock Shares Reserved For Future Issuance Percentage				18.00%
The 2013 Plan [Member] | Employees and Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)										146,700	1,006,602
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)										$ 4.08	$ 7.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)										0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)										234
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								384		0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)										18	132
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)										0
The 2013 Plan [Member] | Underwritten Public Offering [Member]
Minimum Gross Proceeds From Equity Offering Amount Used In Calculation Of Reserved Shares Percentage				$ 5,000,000
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										5 years
2017 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent									85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)									200
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)										84	154
Proceeds from Stock Plans										$ 1,000	$ 56,000
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares)										22

Note 13 - Summary of Stock Op_4

Note 13 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Options outstanding (in shares)	1,008,833	4,098
Options outstanding, weighted average exercise price (in dollars per share)	$ 22.47	$ 4,567.36
Options outstanding, weighted average remaining contractual term (Year)	8 years 328 days	9 years 328 days	7 years 146 days
Options outstanding, aggregate intrinsic value	$ 675,000	$ 3,928,715,000
Options granted (in shares)	146,700	1,006,602
Options granted, weighted average exercise price (in dollars per share)	$ 6.36	$ 11.42
Options exercised (in shares)
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)	(169,134)	(1,867)
Options canceled, weighted average exercise price (in dollars per share)	$ 28.45	$ 4,040.64
Options outstanding (in shares)	986,399	1,008,833	4,098
Options outstanding, weighted average exercise price (in dollars per share)	$ 19.10	$ 22.47	$ 4,567.36
Vested and exercisable and expected to vest (in shares)	923,646
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)	$ 19.77
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	8 years 328 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value	$ 598
Vested and exercisable (in shares)	245,445
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)	$ 45.09
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	8 years 219 days
Vested and exercisable, end of period, aggregate intrinsic value

Note 13 - Summary of Stock Op_5

Note 13 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Options outstanding, number (in shares) | shares	986,399
Options outstanding, weighted average exercise price (in dollars per share)	$ 19.10
Options outstanding, weighted average remaining contractual term (Year)	8 years 328 days
Options exercisable, number exercisable (in shares) | shares	245,445
Options exercisable, weighted average exercise price (in dollars per share)	$ 45.09
Range One [Member]
Exercise price range, lower limit (in dollars per share)	4.45
Exercise price range, upper limit (in dollars per share)	$ 8.91
Options outstanding, number (in shares) | shares	967,288
Options outstanding, weighted average exercise price (in dollars per share)	$ 8.32
Options outstanding, weighted average remaining contractual term (Year)	8 years 328 days
Options exercisable, number exercisable (in shares) | shares	238,900
Options exercisable, weighted average exercise price (in dollars per share)	$ 8.69
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	10.90
Exercise price range, upper limit (in dollars per share)	$ 13.60
Options outstanding, number (in shares) | shares	15,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 12.64
Options outstanding, weighted average remaining contractual term (Year)	9 years 73 days
Options exercisable, number exercisable (in shares) | shares	3,750
Options exercisable, weighted average exercise price (in dollars per share)	$ 13.60
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	380
Exercise price range, upper limit (in dollars per share)	$ 580
Options outstanding, number (in shares) | shares	125
Options outstanding, weighted average exercise price (in dollars per share)	$ 552
Options outstanding, weighted average remaining contractual term (Year)	8 years 146 days
Options exercisable, number exercisable (in shares) | shares	113
Options exercisable, weighted average exercise price (in dollars per share)	$ 567.61
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	1,000
Exercise price range, upper limit (in dollars per share)	$ 1,970
Options outstanding, number (in shares) | shares	1,954
Options outstanding, weighted average exercise price (in dollars per share)	$ 1,426.46
Options outstanding, weighted average remaining contractual term (Year)	7 years 219 days
Options exercisable, number exercisable (in shares) | shares	1,334
Options exercisable, weighted average exercise price (in dollars per share)	$ 1,437.21
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	2,020
Exercise price range, upper limit (in dollars per share)	$ 2,830
Options outstanding, number (in shares) | shares	74
Options outstanding, weighted average exercise price (in dollars per share)	$ 2,501.22
Options outstanding, weighted average remaining contractual term (Year)	7 years
Options exercisable, number exercisable (in shares) | shares	53
Options exercisable, weighted average exercise price (in dollars per share)	$ 2,520.19
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	3,110
Exercise price range, upper limit (in dollars per share)	$ 3,580
Options outstanding, number (in shares) | shares	189
Options outstanding, weighted average exercise price (in dollars per share)	$ 3,439.26
Options outstanding, weighted average remaining contractual term (Year)	7 years 219 days
Options exercisable, number exercisable (in shares) | shares	156
Options exercisable, weighted average exercise price (in dollars per share)	$ 3,455.90
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	4,360
Exercise price range, upper limit (in dollars per share)	$ 4,970
Options outstanding, number (in shares) | shares	619
Options outstanding, weighted average exercise price (in dollars per share)	$ 4,549.77
Options outstanding, weighted average remaining contractual term (Year)	6 years 73 days
Options exercisable, number exercisable (in shares) | shares	510
Options exercisable, weighted average exercise price (in dollars per share)	$ 4,554.04
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	5,010
Exercise price range, upper limit (in dollars per share)	$ 5,670
Options outstanding, number (in shares) | shares	300
Options outstanding, weighted average exercise price (in dollars per share)	$ 5,366
Options outstanding, weighted average remaining contractual term (Year)	6 years 73 days
Options exercisable, number exercisable (in shares) | shares	285
Options exercisable, weighted average exercise price (in dollars per share)	$ 5,356.84
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	6,000
Exercise price range, upper limit (in dollars per share)	$ 6,000
Options outstanding, number (in shares) | shares	138
Options outstanding, weighted average exercise price (in dollars per share)	$ 6,000
Options outstanding, weighted average remaining contractual term (Year)	5 years
Options exercisable, number exercisable (in shares) | shares	138
Options exercisable, weighted average exercise price (in dollars per share)	$ 6,000
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	7,140
Exercise price range, upper limit (in dollars per share)	$ 7,920
Options outstanding, number (in shares) | shares	200
Options outstanding, weighted average exercise price (in dollars per share)	$ 7,679.20
Options outstanding, weighted average remaining contractual term (Year)	4 years 36 days
Options exercisable, number exercisable (in shares) | shares	194
Options exercisable, weighted average exercise price (in dollars per share)	$ 7,676.29
Range Eleven [Member]
Exercise price range, lower limit (in dollars per share)	9,920
Exercise price range, upper limit (in dollars per share)	$ 9,920
Options outstanding, number (in shares) | shares	12
Options outstanding, weighted average exercise price (in dollars per share)	$ 9,920
Options outstanding, weighted average remaining contractual term (Year)	2 years 36 days
Options exercisable, number exercisable (in shares) | shares	12
Options exercisable, weighted average exercise price (in dollars per share)	$ 9,920

Note 13 - Summary of Stock Op_6

Note 13 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expected term (Year)	5 years	6 years
Average volatility	82.00%	70.00%
Risk-free interest rate	0.37%	1.62%
Dividend yield

Note 13 - Summary of Stock Op_7

Note 13 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation expense	$ 2,651	$ 2,400
Cost of Sales [Member]
Stock-based compensation expense	208	135
Research and Development Expense [Member]
Stock-based compensation expense	325	192
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 2,118	$ 2,073

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Expense (Benefit), Total	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 4,352,000	$ (16,506,000)
Deferred Tax Assets, Tax Credit Carryforwards, Research	631,000	527,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0
Unrecognized Tax Benefits, Ending Balance	245,000	$ 223,000	$ 450,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	95,395,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,239,000
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 817,000

Note 14 - Income Taxes - Provis

Note 14 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income tax benefit at statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(3.00%)	(4.00%)
Change in valuation allowance	20.00%	(39.00%)
Debt restructuring	0.00%	6.00%
Limitation on net operating loss and credit carryovers	0.00%	56.00%
Other	4.00%	2.00%
Effective tax rate	0.00%	0.00%

Note 14 - Income Taxes - Signif

Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards	$ 20,891	$ 16,688
Capitalized start up costs	2,866	3,225
Research and development credits	631	527
Accruals and reserves	773	532
Fixed assets and depreciation	(291)	(128)
Total deferred tax assets	25,452	21,100
Valuation allowance	(25,452)	(21,100)
Net deferred tax assets

Note 14 - Income Taxes - Unreco

Note 14 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 223,000	$ 450,000
Additions (deletions) based upon tax positions related to the current year	22,000	(227,000)
Balance	$ 245,000	$ 223,000

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)	38
Related Party Transaction, Amounts of Transaction	$ 1,051,000	$ 4,889,000

Note 16 - Segments and Geogra_3

Note 16 - Segments and Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Long-lived assets	$ 2,759	$ 3,046
UNITED STATES
Long-lived assets	2,622	2,818
Asia Pacific [Member]
Long-lived assets	76	64
CANADA
Long-lived assets	54	142
Europe [Member]
Long-lived assets	$ 7	$ 22

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - USD ($)

Jan. 19, 2021

Jan. 01, 2021

Jun. 30, 2021

Mar. 17, 2021

Jan. 31, 2021

Jan. 31, 2020

Jan. 31, 2019

Jan. 18, 2021

Dec. 31, 2020

Apr. 20, 2020

Apr. 15, 2020

Jan. 01, 2020

Dec. 31, 2019

Nov. 26, 2019

Jan. 01, 2019

Dec. 31, 2018

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

2,473,785

Sublease Agreement for Relocation of Headquarters [Member] | Forecast [Member]

Lessee, Operating Lease, Rent Abatement

$ 19,000

The 2013 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)

263,993

2,044

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

1,451,246

1,451,246

1,187,253

6,958

4,914

Series A-2 and Series B-2 Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 6.371

Warrants and Rights Outstanding, Term (Year)

5 years

Series A and Series B Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 6.10

$ 15.50

Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters [Member]

Lessee, Operating Lease, Renewal Term (Month)

2 years 300 days

Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters First Year Extension [Member]

Lessee, Operating Lease, Monthly Gross Rent

$ 21,028

Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters Second Year Extension [Member]

Lessee, Operating Lease, Monthly Gross Rent

21,643

Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters Third Year Extension [Member]

Lessee, Operating Lease, Monthly Gross Rent

$ 22,258

Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

690,000

Subsequent Event [Member] | The 2013 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)

307,705

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

1,758,951

Subsequent Event [Member] | Series C Preferred Stock [Member]

Preferred Stock, Shares Outstanding, Ending Balance (in shares)

0

Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 3.40

$ 6.371

Subsequent Event [Member] | Series A and Series B Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 3.40

$ 6.10

Subsequent Event [Member] | Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]

Warrants Per Unit (in shares)

1

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 3.40

Warrants and Rights Outstanding, Term (Year)

5 years

Subsequent Event [Member] | Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]

Warrants Per Unit (in shares)

1

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 3.40

Warrants and Rights Outstanding, Term (Year)

5 years

January 2021 Offering [Member] | Subsequent Event [Member]

Proceeds from Issuance or Sale of Equity, Total

$ 27,600,000

Shares Issued, Price Per Share (in dollars per share)

$ 3.40

Proceeds from Issuance or Sale of Equity, Net of Issuance Costs

$ 25,223,000

January 2021 Offering [Member] | Subsequent Event [Member] | Series C Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

2,450,880

Convertible Preferred Stock, Shares Issued upon Conversion (in shares)

1

January 2021 Offering [Member] | Subsequent Event [Member] | Class A Units [Member]

Units Issued, Shares (in shares)

4,607,940

Shares Issued, Price Per Share (in dollars per share)

$ 3.40

Common Shares Per Unit (in shares)

1

January 2021 Offering [Member] | Subsequent Event [Member] | Class B Units [Member]

Units Issued, Shares (in shares)

2,450,880

Shares Issued, Price Per Share (in dollars per share)

$ 3.40

Series C Convertible Preferred Stock Per Unit (in shares)

1

Over-Allotment Option [Member] | Subsequent Event [Member]

Stock Issued During Period, Shares, New Issues (in shares)

1,058,820

Over-Allotment Option [Member] | Subsequent Event [Member] | Warrants Issued in Connection with January 2021 Offering [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

1,058,820